Pila Pharma AB (publ) (FRA:5KC)

Market Cap	6.68M -19.6%
Revenue (ttm)	104.11K +42.6%
Net Income	-1.57M
EPS	-0.05
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	0.1245
Previous Close	0.1385
Day's Range	0.1245 - 0.1350
52-Week Range	0.0869 - 0.2500
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 27, 2026

About Pila Pharma AB

Pila Pharma AB (publ) operates as a clinical stage biotech company in Sweden. The company develops XEN-D0501, a TRPV1 antagonist in Phase 2a trial for obesity, diabetes, and heart failure; Phase 1 trial for erythromelalgia, inflammation pain, and rare diseases; and preclinical trial for abdominal aorta aneurism and cardiovascular diseases. Pila Pharma AB (publ) was incorporated in 2014 and is headquartered in Malmö, Sweden.

• Industry: Pharmaceutical Preparations
• Founded: 2014
• Employees: 1
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 5KC

Financial Performance

In 2025, Pila Pharma AB's revenue was 1.13 million, an increase of 42.65% compared to the previous year's 789,889. Losses were -17.00 million, 51.3% more than in 2024.

Financial numbers in SEK

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Aug 27, 2026

Data Sources Report a data error